FierceBiotechOriginal article
{"a":[{"_":"Silence brings the noise to Takeda with phase 2 blood cancer win","$":{"href":"/biotech/silence-brings-noise-takeda-phase-2-blood-cancer-win","hreflang":"en"}}]}
Phase 2positivedivesiranrusfertidePositive
AI Analysis
Summary
Silence Therapeutics' divesiran met its primary endpoint in a phase 2 trial for blood cancer, positioning the company to advance to late-phase development as a potential competitor to Takeda and Protagonist Therapeutics' rusfertide.
Clinical Trial Data
Phase
Phase 2
Primary Endpoint
Met
Outcome Details
Primary endpoint hit in phase 2 trial
Importance:7/10
Sentiment:
0.80
Phase 2 datablood cancercompetitive landscapeclinical trial success
Read the original article
Published by FierceBiotech on August 10, 2026 4:36 AM